Research Topics
Genomes and Genes | Rahul RaySummaryAffiliation: Boston University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine modelRahul Ray
Department of Medicine, Boston University School of Medicine, 85 East Newton Street, M 1002, Boston, MA 02118, USA
Anticancer Res 32:727-31. 2012..Our results suggest an important role of dietary vitamin D as a preventive agent in androgen-insensitive PC...
1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of actionRahul Ray
Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Bioorg Med Chem Lett 21:2537-40. 2011..We also report that mechanism of action of 1,25(OH)(2)D(3)-3-BE may involve reduction of its catabolism, as evidenced by the reduced and delayed expression of 1α,25-dihydroxyvitamin D(3)-24-hydroxylase (CYP24) gene in cellular assays...- Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cellsNarasimha Swamy
Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, USA
Clin Cancer Res 10:8018-27. 2004..Collectively, these results strongly suggested that 25-OH-D(3)-3-BE has a strong potential as a therapeutic agent for androgen-sensitive and androgen-refractory prostate cancer... - 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cellsNarasimha Swamy
Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, USA
J Cell Biochem 89:909-16. 2003..Therefore, these results raise the possibility that 1,25(OH)(2)D(3)-3-BE or similar VDR-cross linking analogs of 1,25(OH)(2)D(3) might be considered for further development as potential candidates for prostate cancer... - Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implicationsTaner Kaya
Boston University, Boston, MA 02215, USA
Bioorg Chem 37:57-63. 2009..Therefore, we conclude that the beta-hairpin region (modified by 1,25(OH)(2)D(3)-3-BE) is most important for growth inhibition by 1,25(OH)(2)D(3), while helices 3 and 6 are less important for such activity... - Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugateAna Fernandez Gacio
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Cell Biochem 99:665-70. 2006..Therefore, it is a potential candidate for ER-targeted photodynamic therapy of cancers (PDT) of tissues and organs that respond to estrogens/antiestrogens... - Nuclear estrogen receptor targeted photodynamic therapy: selective uptake and killing of MCF-7 breast cancer cells by a C17alpha-alkynylestradiol-porphyrin conjugateNarasimha Swamy
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Cell Biochem 99:966-77. 2006.... - A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert
Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Cancer Prev Res (Phila) 3:1596-607. 2010.... - Crystal structure of the complex between actin and human vitamin D-binding protein at 2.5 A resolutionJames F Head
Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Biochemistry 41:9015-20. 2002..The larger "footprint" of DBP on actin also leads to an overlap with the actin-binding site of gelsolin domain I... 
Internalization of a C17α-alkynylestradiol-porphyrin conjugate into estrogen receptor positive MCF-7 breast cancer cellsSara Sadler
Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA
Bioorg Med Chem Lett 21:4638-41. 2011..This study is a direct demonstration of our hypothesis about ER-mediated internalization of estrogen-porphyrin conjugates...- Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cellsKelly S Persons
Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Anticancer Res 30:1875-80. 2010..In conclusion, 1,25(OH)(2)D(3)-3-BE displays a strong therapeutic potential, alone and in combination with AICAR, in pancreatic cancer... - Biochemical and preliminary crystallographic characterization of the vitamin D sterol- and actin-binding by human vitamin D-binding proteinNarasimha Swamy
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Arch Biochem Biophys 402:14-23. 2002.... - Cross-talk among structural domains of human DBP upon binding 25-hydroxyvitamin DArjun Ray
Bioorganic Chemistry and Structural Biology, Department of Medicine, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, USA
Biochem Biophys Res Commun 365:746-50. 2008..These results provide a direct evidence of cross-talk among the structural domains of DBP... - Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in miceOliver Kisker
Division of Surgical Research, Children's Hospital, Boston, MA 02115, USA
Neoplasia 5:32-40. 2003..Taken together, these data suggest that DBP-maf is an antiangiogenic molecule that can act directly on endothelium as well as stimulate macrophages to attack both the endothelial and tumor cell compartment of a growing malignancy... - Fatty acid-binding site environments of serum vitamin D-binding protein and albumin are differentNarasimha Swamy
Bioorganic Chemistry and Structural Biology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Bioorg Chem 36:165-8. 2008.... - An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cellsNarasimha Swamy
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118, USA
Bioorg Med Chem 10:3237-43. 2002..Therefore, ER-binding conjugates of estradiol and porphyrins could potentially be used for ER-targeted photodynamic therapy of hormone-sensitive cancers of breast, ovary, gonads etc... - Affinity labeling of the nuclear vitamin D receptor with nonsteroidal alkylating agentsAna Fernandez-Gacio
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, USA
Bioorg Med Chem Lett 13:213-6. 2003..Synthesis of an affinity alkylating non steroidal mimic of 1alpha,25-dihydroxyvitamin D(3) and its radiolabeled counterpart is presented. We also report the affinity labeling of the VDR-ligand binding domain (VDR-LBD) with this analogue... - The C(19) position of 25-hydroxyvitamin D(3) faces outward in the vitamin D sterol-binding pocket of vitamin D-binding proteinJames K Addo
Bioorganic Chemistry and Structural Biology, Section in Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Bioorg Med Chem Lett 12:279-81. 2002.... - Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cellsJames R Lambert
Department of Pathology, University of Colorado Health Science Center, Aurora, CO, USA
Biochem Biophys Res Commun 361:189-95. 2007..Furthermore, we carried out cellular uptake and serum stability studies of 25-OH-D(3)-3-BE to demonstrate potential therapeutic applicability of 25-OH-D(3)-3-BE in hormone-sensitive and hormone-insensitive prostate cancer...